ES2706493T3 - Complejos de aminoácidos minerales de agentes activos - Google Patents

Complejos de aminoácidos minerales de agentes activos Download PDF

Info

Publication number
ES2706493T3
ES2706493T3 ES15734490T ES15734490T ES2706493T3 ES 2706493 T3 ES2706493 T3 ES 2706493T3 ES 15734490 T ES15734490 T ES 15734490T ES 15734490 T ES15734490 T ES 15734490T ES 2706493 T3 ES2706493 T3 ES 2706493T3
Authority
ES
Spain
Prior art keywords
acid
omega
composition
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15734490T
Other languages
English (en)
Spanish (es)
Inventor
Frank Sciavolino
Gary Mathias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thetis Pharmaceuticals LLC
Original Assignee
Thetis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thetis Pharmaceuticals LLC filed Critical Thetis Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2706493T3 publication Critical patent/ES2706493T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/015—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/76—Metal complexes of amino carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/02—Magnesium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04—Calcium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/06—Zinc compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pediatric Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
ES15734490T 2014-06-18 2015-06-12 Complejos de aminoácidos minerales de agentes activos Active ES2706493T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013904P 2014-06-18 2014-06-18
US201462058491P 2014-10-01 2014-10-01
PCT/US2015/035686 WO2015195491A1 (en) 2014-06-18 2015-06-12 Mineral amino-acid complexes of active agents

Publications (1)

Publication Number Publication Date
ES2706493T3 true ES2706493T3 (es) 2019-03-29

Family

ID=53514393

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15734490T Active ES2706493T3 (es) 2014-06-18 2015-06-12 Complejos de aminoácidos minerales de agentes activos

Country Status (14)

Country Link
US (1) US9999626B2 (enExample)
EP (1) EP3157936B1 (enExample)
JP (1) JP2017526623A (enExample)
KR (1) KR20170023061A (enExample)
CN (1) CN107074884A (enExample)
AU (1) AU2015277509A1 (enExample)
BR (1) BR112016029476A2 (enExample)
CA (1) CA2951923A1 (enExample)
DK (1) DK3157936T3 (enExample)
EA (1) EA201692548A1 (enExample)
ES (1) ES2706493T3 (enExample)
IL (1) IL249455A0 (enExample)
MX (1) MX2016016830A (enExample)
WO (1) WO2015195491A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
EP3248467A1 (de) * 2016-05-25 2017-11-29 Evonik Technochemie GmbH Verfahren zur herstellung einer zusammensetzung enthaltend omega-3-fettsäure-l-lysin-salze
JP6906047B2 (ja) * 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
CN109661238B (zh) * 2016-07-27 2023-07-25 哈里斯制药公司 治疗红细胞疾病的治疗组合
EP3275458A1 (en) * 2016-07-27 2018-01-31 Hartis-Pharma Sarl Combination therapy to treat sickle cell disease and restore rbc functions
SE542106C2 (en) 2016-08-26 2020-02-25 Atif M Dabdoub Dietary macro/micronutritional supplement for patients undergoing kidney dialysis
CN106631848B (zh) * 2017-01-03 2018-11-13 河北农业大学 一种以海湾扇贝壳为钙源的赖氨酸螯合钙制备方法
WO2019165222A1 (en) * 2018-02-23 2019-08-29 Dabdoub Atif Dietary macro/micronutritional supplement and applications thereof
WO2019195513A1 (en) * 2018-04-04 2019-10-10 Price John D Metallo-liothyronine
CN109294114B (zh) * 2018-09-04 2021-03-09 浙江工业大学 精氨酸金属络合物、复配型热稳定剂及其应用
PL431268A1 (pl) * 2019-09-25 2021-04-06 ebiga-VISION GMBH Kompozycja suplementu diety i/lub dodatku odżywczego do żywności, jednostkowa postać dawkowania tej kompozycji i ich zastosowanie do poprawy jakości widzenia w tym wrażliwości na kontrast u osób potrzebujących takiej poprawy, w tym osób cierpiących na co najmniej jedną chorobę oczu, zwłaszcza na męty szklistkowe
US20210228557A1 (en) * 2020-01-29 2021-07-29 Healthy Directions, LLC Therapeutic compositions comprising coenzyme q10
BR102022016500A2 (pt) * 2022-08-18 2024-02-27 Universidade Estadual De Campinas Processo de obtenção de composições à base de compostos multifuncionais, composições à base de compostos multifuncionais assim obtidas e seu uso

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599152A (en) 1985-05-24 1986-07-08 Albion Laboratories Pure amino acid chelates
US4863898A (en) * 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ES2084722T3 (es) 1990-05-29 1996-05-16 Boston Ocular Res Composicion para tratamiento del ojo seco.
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
IT1264987B1 (it) * 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
WO1999055320A1 (en) 1998-04-29 1999-11-04 Sumitomo Pharmaceuticals Co., Ltd. Oral formulation comprising biguanide and an organic acid
JP4526622B2 (ja) * 1998-10-23 2010-08-18 北興化学工業株式会社 農園芸用種子消毒剤および種子の消毒方法
JP2000212145A (ja) * 1999-01-22 2000-08-02 Hokko Chem Ind Co Ltd Ｎε―アシル―４―オキサリジンおよびその製造用中間体
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
KR100784752B1 (ko) 2000-02-04 2007-12-13 다케다 야쿠힌 고교 가부시키가이샤 안정한 에멀젼 조성물
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
DE10102050A1 (de) 2001-01-17 2002-07-18 Basf Ag Zubereitung zur Verbesserung der Nahrungsverwertung
JP4220247B2 (ja) 2001-03-29 2009-02-04 ビーエーエスエフ ソシエタス・ヨーロピア 共役不飽和グリセリド混合物及びその製造方法
EP1429602B1 (en) 2001-08-31 2009-12-16 Rutgers, The State University Of New Jersey Methods for treating disorders using plant extracts
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20030220301A1 (en) 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
AU2003266014B2 (en) 2002-05-06 2009-05-14 Alnylam Pharmaceuticals, Inc. Methods for delivery of nucleic acids
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US7214387B2 (en) 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
EP2384750A1 (en) 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
US7547454B2 (en) * 2002-11-07 2009-06-16 Shyam K Gupta Hydroxy acid complexes for antiaging and skin renovation
JP2004175790A (ja) * 2002-11-12 2004-06-24 Arita Junichi α−グルコシダーゼ阻害作用を有する亜鉛含有物
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
PL377614A1 (pl) 2003-03-18 2006-02-06 Novartis Ag Kompozycje zawierające kwasy tłuszczowe i aminokwasy
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20080045559A1 (en) 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2005041926A1 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
CA2554617A1 (en) 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
EP1591114A1 (en) 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20060003976A1 (en) 2004-06-04 2006-01-05 Yuehua Zhang Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
CN101094683A (zh) 2004-10-29 2007-12-26 J·坎贝尔－托夫特 从催吐萝芙木和酸橙中分离的抗糖尿病提取物及其使用方法
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
EP1898922A4 (en) 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
JP2009526747A (ja) 2006-02-16 2009-07-23 武田薬品工業株式会社 環状アミン化合物および高血圧の予防・治療のための用途
US20090047340A1 (en) 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
US7973073B2 (en) 2006-06-16 2011-07-05 Indigene Pharmaceuticals, Inc. Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
US20120189569A1 (en) 2006-08-06 2012-07-26 Bioderm Research Hydroxy Acid Complexes for Skin Renovation and Clarity
KR101438177B1 (ko) 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
US20100105773A1 (en) 2006-11-09 2010-04-29 The Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
WO2008093984A1 (en) 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20090227560A1 (en) 2007-04-27 2009-09-10 Takanobu Kuroita Substituted imidazole compound and use thereof
CL2008001163A1 (es) 2007-04-27 2008-12-19 Takeda Pharmaceutical Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension.
US20090054513A1 (en) 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
WO2009038396A2 (en) 2007-09-21 2009-03-26 Hanall Pharmaceutical Company. Ltd N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
JP5441705B2 (ja) 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
JP2011519915A (ja) 2008-05-05 2011-07-14 オラムド エルティーディー． エクセナチドの経口投与用の方法および組成物
PE20110067A1 (es) 2008-06-19 2011-02-18 Takeda Pharmaceutical Derivados de piperidina como inhibidores de renina
ES2450148T3 (es) 2008-06-26 2014-03-24 Laboratorios Silanes, S.A. De C.V. Una nueva sal de glicinato de metformina para el control de la glucosa en sangre
FR2934519B1 (fr) 2008-08-01 2013-06-28 Oreal Procede de fabrication d'un premier recipient de produit cosmetique, moule, col et recipient associes
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
PL217815B1 (pl) * 2009-12-14 2014-08-29 Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością Napój izotoniczny z chelatami
US8178707B2 (en) 2010-03-25 2012-05-15 Jost Chemical Company Co-precipitated salts of fatty acids
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2012141316A1 (ja) 2011-04-13 2012-10-18 味の素株式会社 栄養組成物
SG11201403805WA (en) 2012-01-06 2014-08-28 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
MX2015000408A (es) * 2012-07-10 2015-07-14 Thetis Pharmaceuticals Llc Forma de triple sal de metformina.
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014011895A2 (en) 2012-07-11 2014-01-16 Thetis Pharmaceuticals Llc High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof
AU2012227298B2 (en) 2012-09-25 2015-02-12 Jost Chemical Co. Co-precipitated salts of fatty acids
TW201416726A (zh) 2012-10-26 2014-05-01 Dongguan Masstop Liquid Crystal Display Co Ltd 具有觸控功能之彩色濾光片基板
CN103340300A (zh) * 2013-06-06 2013-10-09 李才平 一种绿色生态鲫鱼饲料的配制方法
EP3140316A1 (en) * 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN104430341B (zh) * 2014-12-10 2016-09-28 青岛大学 天然有机酸根褐藻氨酸螯合物在农用制剂中的应用

Also Published As

Publication number Publication date
US20160199385A1 (en) 2016-07-14
BR112016029476A2 (pt) 2017-08-22
AU2015277509A1 (en) 2017-01-05
CA2951923A1 (en) 2015-12-23
DK3157936T3 (en) 2019-02-04
US9999626B2 (en) 2018-06-19
EP3157936A1 (en) 2017-04-26
WO2015195491A1 (en) 2015-12-23
IL249455A0 (en) 2017-02-28
KR20170023061A (ko) 2017-03-02
MX2016016830A (es) 2017-07-07
CN107074884A (zh) 2017-08-18
EA201692548A1 (ru) 2017-10-31
EP3157936B1 (en) 2018-10-17
JP2017526623A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
ES2706493T3 (es) Complejos de aminoácidos minerales de agentes activos
ES2841344T3 (es) Composición autoemulsionante de ácidos grasos omega-3
US6417233B1 (en) Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiguinones and methods of using same
ES2585066T3 (es) Composiciones para el tratamiento de trastornos neurológicos
ES2999020T3 (en) Carrier comprising non-neutralised tocopheryl phosphate
KR101100078B1 (ko) 관절염 치료를 위한 약제학적 조성물
US9242008B2 (en) Mineral amino-acid complexes of fatty acids
US20170119841A1 (en) Amino acid salts of unsaturated fatty acids
ES2997373T3 (en) Method for preparing a composition comprising cetylated fatty acids
JP2010522146A (ja) タンパク質のカルボニル化の増加の予防およびそれを原因とする病変の治療のためのシトルリンの使用
US9505709B2 (en) Compositions and methods relating to ionic salts of peptides
AU2013202114B2 (en) Acne treatment
ES2964978T3 (es) Ester alquílico del ácido 10-hidroxi-cis-12-octadecenoico y su uso
US10925845B2 (en) Stability of vitamin D in β-hydroxy-β-methylbutyrate (HMB)
JP6625986B2 (ja) カカオポリフェノール及び好酸球性食道炎の治療又は予防におけるその使用
EP1669066A1 (en) Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient
CN112955158A (zh) 含铁组合物及其用途
WO2017079391A1 (en) Amino acid salts of saturated fatty acids
US12161654B2 (en) Stability of vitamin D in β-hydroxy-β-methylbutyrate (HMB)
US20050250674A1 (en) Nutritional and food supplement preparation comprising creatine and orotic acid complexes, derivatives and analogs
RU2021108388A (ru) Железосодержащая композиция и ее применение
KR20220050082A (ko) β-하이드록시-β메틸부티레이트(HMB)에서의 비타민 D의 안정성
EP3836803A1 (en) Stability of vitamin d in beta-hydroxy- beta-methylbutyrate (hmb)